financetom
Business
financetom
/
Business
/
AstraZeneca Caps Out-of-Pocket Costs for Inhaled Respiratory Medicines in US
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AstraZeneca Caps Out-of-Pocket Costs for Inhaled Respiratory Medicines in US
Mar 18, 2024 6:47 AM

09:28 AM EDT, 03/18/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that eligible patients will not have to pay more than $35 per month for the pharmaceutical giant's US inhaled respiratory medicines, beginning June 1.

The medicines include Airsupra, Bevespi Aerosphere, Breztri Aerosphere, and Symbicort.

Price: 65.96, Change: -0.35, Percent Change: -0.53

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Uranium Royalty Acquires Existing Royalty On Cameco's Advanced Stage Millennium And Cree Extension Uranium Projects
BRIEF-Uranium Royalty Acquires Existing Royalty On Cameco's Advanced Stage Millennium And Cree Extension Uranium Projects
Nov 3, 2024
Oct 28 (Reuters) - Uranium Royalty Corp ( UROY ): * URANIUM ROYALTY ACQUIRES EXISTING ROYALTY ON CAMECO'S ADVANCED STAGE MILLENNIUM AND CREE EXTENSION URANIUM PROJECTS * URANIUM ROYALTY CORP ( UROY )- PROPOSED DEAL FOR FOR TOTAL CASH CONSIDERATION OF $6 MILLION Source text: Further company coverage: ...
Alliance Resource Partners' Q3 Earnings, Revenue Fall
Alliance Resource Partners' Q3 Earnings, Revenue Fall
Nov 3, 2024
07:39 AM EDT, 10/28/2024 (MT Newswires) -- Alliance Resource Partners ( ARLP ) reported Q3 earnings Monday of $0.66 per diluted limited partner unit, down from $1.18 a year earlier. Two analysts polled by Capital IQ expected normalized earnings of $0.82. Total revenue for the quarter ended Sept. 30 was $613.6 million, down from $636.5 million. Three analysts polled by...
Commerzbank Asks If Russia's Central Bank Is Overdoing It in Monetary Tightening
Commerzbank Asks If Russia's Central Bank Is Overdoing It in Monetary Tightening
Nov 3, 2024
07:38 AM EDT, 10/28/2024 (MT Newswires) -- Russia's central bank (CBR) has always been a credible and prudent central bank in the emerging market world, said Commerzbank. The bank admired its past decisions when the CBR hiked rates right after government figures demanded rate cuts from time to time. Impeccable credentials notwithstanding, Commerzbank now asked whether or not CBR might...
Biogen Says Phase 2 Trial of Felzartamab Shows 'Substantial Reductions' in Proteinuria Levels, Kidney Function Stabilization
Biogen Says Phase 2 Trial of Felzartamab Shows 'Substantial Reductions' in Proteinuria Levels, Kidney Function Stabilization
Nov 3, 2024
07:35 AM EDT, 10/28/2024 (MT Newswires) -- Biogen (BIIB) said late Saturday that a phase 2 clinical trial assessing felzartamab demonstrated substantial reductions in proteinuria levels, stabilization of kidney function, and sustained treatment impact over 18 months following the investigational drug's last dose. The trial enrolled 54 participants to evaluate felzartamab's safety and efficacy in patients with Immunoglobulin A nephropathy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved